Vergleich

IL-33 Recombinant Protein

Hersteller ProSci
Kategorie
Typ Proteins Recombinant
Specific against other
Format Lyophilized
Menge 10 ug
ArtNr PRS-90-557-10ug
eClass 6.1 34160400
eClass 9.0 42020190
Lieferbar
Applications
This recombinant proteins is for research use only.
Applications
This recombinant proteins is for research use only.
Buffer
Lyophilized. Contains PBS + 1mM DTT
Storage Conditions
After reconstitution, prepare aliquots and store at -20˚ C. Avoid freeze/thaw cycles. PBS containing at least 0.1% BSA should be used for further dilutions
Disclaimer
Products are intended for laboratory research purposes only and should be used by qualified personnel only. They are not intended for use in humans. ProSci is not liable for damages or injuries resulting from receipt and/or use of ProSci materials. Please refer to the Material Safety Data Sheet (MSDS) for safe storage, handling, and use procedures.
Predicted Molecular Weight
~17kDa (SDS-PAGE); Monomer (Size Exclusion Chromatography)
Purity
≥95% (SDS-PAGE).

Endotoxin level is less than <0.01EU/μg purified protein (LAL test).
Background
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3) / ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. IL-33 facilitates Treg expansion in vitro and in vivo. Recently, IL-33 has been involved in adipocyte differentiation. The biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S/C232S protect IL-33 from oxidation and increase its activity.
1St Image Caption3
Activation in vivo of Innate Lymphoid Cells 2 (ILC2) by IL-33 (oxidation resistant) (human) (rec.) (untagged). Method: C57BL/6 mice were injected daily for 3 days with PBS (Figure A) or IL-33 (oxidation resistant) (human) (rec.) (untagged) (at 0.4ug per mouse) (Figure B). At day 4, cells from bone marrows were stained and analyzed by flow cytometry. Levels of ST2 and KLRG1 on Innate Lymphoid Cells (gated as lineage negative, CD127 positive cells) are shown. Picture courtesy of Dr G.Verdeil / Dr S. Trabanelli (Camilla Jandus Group, Department of Fundamental Oncology, University of Lausanne)
Concentration
0.1mg/ml
Accession #
Q2YEJ5
Ncbi Organism
Homo sapiens
Sequence
Human IL-33 (aa 112-270) is untagged. Amino acids C208 and C232 have been mutated to serine to protect IL-33 from oxidation.
Biological Activity
Activates human and mouse ST2-dependent NF-kappa B pathway. Activates in vivo Innate Lymphoid Cells 2 (ILC2) at 0.4ug /ml.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 10 ug
Lieferbar: In stock
lieferbar

Lieferung vsl. bis 02.05.2024 

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen